Clinical boundary
Payment should not mean automatic prescribing
A safe online peptide program can collect payment information before or during intake, but the medical decision should still come from a licensed clinician after reviewing the patient’s history, medications, goals, allergies, pregnancy context, labs or vitals when relevant, and product-specific risks. Checkout language should not imply that approval is guaranteed just because a card was charged.
- Ask whether the clinician can decline, delay, request labs or records, change the product, or recommend local care before medication is dispensed.
- For GLP-1 medicines, payment timing should not bypass diabetes-medication review, pregnancy questions, GI history, kidney risk, gallbladder or pancreatitis history, thyroid cancer or MEN2 warnings, or branded-versus-compounded distinctions.
- For sermorelin, PT-141, NAD+, glutathione, GHK-Cu, and methylene blue, the screening questions should match the route and safety profile instead of using one generic checkout path.